Founded in 2022, OpenEvidence develops an AI reasoning system for medical professionals, offering rapid, evidence-based answers grounded in peer-reviewed research. Often regarded as the “ChatGPT for doctors,” the platform differentiates itself by training exclusively on verified medical literature — including the Journal of the American Medical Association (JAMA) and the New England Journal of Medicine (NEJM) — to ensure factual reliability and clinical precision.

The company describes its mission as enabling physicians to make faster, better-informed decisions by surfacing trusted medical evidence directly at the point of care. Unlike consumer chatbots, OpenEvidence limits access to verified healthcare providers, maintaining a secure environment aligned with professional standards and regulatory compliance.

According to The New York Times, OpenEvidence closed its latest $200 million funding round at a $6 billion valuation, barely three months after securing $210 million at $3.5 billion.

The new round was led by Google Ventures (GV), with participation from a powerhouse roster of investors including Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft Ventures.

The doubling of its valuation in such a short window highlights both the intense investor appetite for vertical AI platforms and the rapid acceleration of AI adoption in healthcare, a market expected to exceed $200 billion globally by 2030.

Since mid-2025, OpenEvidence has nearly doubled its monthly clinical consultations to 15 million, according to data shared with the Times.

Doctors and nurses use the system to confirm treatment guidelines, reference dosage standards, or cross-check diagnostic information against established medical research — all within seconds.

While access is free for licensed practitioners, OpenEvidence monetizes through sponsorships and medical advertising partnerships, positioning itself as a hybrid model that prioritizes accessibility while building sustainable revenue.

The company’s rapid scaling demonstrates growing trust among healthcare professionals and reflects how AI copilots are beginning to augment real-world medical workflows rather than simply assist in academic research.

OpenEvidence’s success underscores a broader trend toward domain-specific AI systems — purpose-built tools fine-tuned for regulated, high-stakes industries like healthcare, law, and finance.

By focusing on precision and verified data sources, these platforms avoid many of the pitfalls seen in general-purpose AI models, such as hallucination and misinformation. For investors, the rise of vertical AI represents a clear shift from hype to utility — and a signal that real-world adoption now drives valuation growth.

Q1: What is OpenEvidence?
A: It’s an AI-powered clinical assistant trained on verified medical literature, designed to help doctors and nurses quickly access evidence-based medical knowledge.

Q2: How much has OpenEvidence raised so far?
A: The company has raised more than $410 million in 2025 alone, reaching a $6 billion valuation.

Q3: Who led the latest funding round?
A: The round was led by Google Ventures, with participation from Sequoia, Kleiner Perkins, Blackstone, and others.

Q4: How fast is OpenEvidence growing?
A: Its monthly clinical consultations have nearly doubled to 15 million since July 2025.

Q5: Why is OpenEvidence significant?
A: It’s among the first AI platforms to achieve large-scale adoption in clinical medicine, signaling how vertical AI can transform specialized professions.

The rise of OpenEvidence marks a pivotal shift in the trajectory of artificial intelligence in medicine. For years, AI in healthcare focused on imaging and diagnostics; now it’s moving directly into the decision-making process itself — where clinical reasoning, safety, and accountability converge.

By limiting its training data to peer-reviewed sources like JAMA and NEJM, OpenEvidence signals a new standard for trustworthy AI — one that values precision over personality. In doing so, it challenges the idea that large, generalized models like ChatGPT can safely serve in high-stakes environments without domain-specific grounding.

The company’s meteoric valuation isn’t just about investor enthusiasm; it reflects a deeper belief that AI copilots tailored for regulated fields — medicine, law, finance — will define the next decade of enterprise innovation. The challenge ahead lies not in proving what AI can do, but in ensuring it meets the standards of clinical rigor, data transparency, and ethical accountability that define professional trust.

If OpenEvidence succeeds, it could redefine how clinicians interact with information — shifting from static reference materials to dynamic, evidence-based reasoning systems that become as essential as the stethoscope itself.

Editor’s Note: This article was created by Alicia Shapiro, CMO of AiNews.com, with writing, image, and idea-generation support from ChatGPT, an AI assistant used for research and drafting. However, the final perspective and editorial choices are solely Alicia Shapiro’s. Special thanks to ChatGPT for assistance with research and editorial support in crafting this article.